Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Brixton Biosciences Inks $33M in Series B Funding

2024-05-31
CAMBRIDGE, MA, Brixton Biosciences, a clinical stage life sciences company, announced that it closed a Series B funding round of $33M.
Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors